No Data
No Data
Jiangsu Sinopep-Allsino Biopharmaceutical's H1 Profit Surges Fivefold
Jiangsu Sinopep-Allsino Biopharmaceutical: Summary of Half-Year Report in 2024.
Jiangsu Sinopep-Allsino Biopharmaceutical: Half-year report for the year 2024.
Nuo Tai Biotech (688076.SH): Passed the pharmaceutical GMP compliance inspection.
On August 16th, Gelunhui reported that Notai Biology (688076.SH) recently received the "Certificate of Export of Active Pharmaceutical Ingredient to the European Union" and the "Notice of Conformity of GMP Inspection of Drugs" issued by Jiangsu Provincial Drug Administration, and the production lines of raw materials (liraglutide, only for processing documents for export to the European Union) in workshop 106 of the Lianyungang factory, production lines of raw materials (exenatide) in workshop 106, and production lines of raw materials (acetic acid sucrose) in workshop 101, have been inspected on site by the Jiangsu Provincial Drug Administration, and met the requirements of the "Drug Production Quality Management Standard".
Notch Biopharma (688076.SH): The active pharmaceutical ingredient of telbivudine is in the process validation stage.
On August 9th, Gelunhui reported that Notai Biology (688076.SH) stated on their interactive platform that the technology verification stage has been reached with their active pharmaceutical ingredient, Telbivudine, which can be used for customer research and development approval. Sales revenues of 59.4246 million yuan have been generated in 2023.
Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd.'s (SHSE:688076) Intrinsic Value Is Potentially 62% Above Its Share Price
No Data